View in EDS HTML Full Text PDF Full Text

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.

Saved in:
Bibliographic Details
Title: CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.
Authors: Tirado N; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain., Fidyt K; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain., Mansilla MJ; OneChain Immunotherapeutics S.L, Barcelona, Spain., Garcia-Perez A; OneChain Immunotherapeutics S.L, Barcelona, Spain., Martínez-Moreno A; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain., Vinyoles M; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain., Alcain J; Centro de Biología Molecular Severo Ochoa CSIC-UAM, Madrid, Spain., García-Peydró M; Centro de Biología Molecular Severo Ochoa CSIC-UAM, Madrid, Spain., Roca-Ho H; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain., Fernandez-Fuentes N; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain., Guerrero-Murillo M; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain., Falgàs A; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Velasco-Hernandez T; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain.; Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain., Bueno C; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Panelli P; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain., Mulens-Arias V; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain., Apostolov A; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain., Engel P; Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain., González EA; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain.; Department of Immunology, Hospital Clínic de Barcelona, Barcelona, Spain., Vick B; Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health (HMGU), Munich, Germany., Jeremias I; Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Munich, German Research Center for Environmental Health (HMGU), Munich, Germany.; Department of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital, LMU Munich, Munich, Germany., Caye-Eude A; Department of Genetics, University Hospital Robert Debré; INSERM Institut de Recherche Saint Louis, Paris, France., Baruchel A; Department of Genetics, University Hospital Robert Debré; INSERM Institut de Recherche Saint Louis, Paris, France., Cavé H; Department of Genetics, University Hospital Robert Debré; INSERM Institut de Recherche Saint Louis, Paris, France., Genescà E; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain., Ribera J; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.; Department of Hematology, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, Spain., Díaz-Beyá M; Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain., Martínez-Sánchez MV; Immunology Service, Clinical University Hospital Virgen de la Arrixaca, Instituto Murciano de Investigación Sanitaria (IMIB), University of Murcia, Murcia, Spain., Fuster JL; Sección de Oncohematología Pediátrica, Hospital Clínico Universitario Virgen de la Arrixaca; Instituto Murciano de Investigación Sanitaria (IMIB), University of Murcia, Murcia, Spain., Escudero López A; Department of Genetics, Institute of Medical and Molecular Genetics (INGEMM), La Paz University Hospital, Madrid, Spain., Minguillón J; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain.; CIBERER-ISCIII, IdiPAZ-CNIO Translational Research Unit in Pediatric Hemato-Oncology, La Paz University Hospital Research Institute; Spanish National Cancer Center, Madrid, Spain.; Advanced Therapies Mixed Unit, CIEMAT/IIS-FJD, Madrid, Spain., Pérez-Martínez A; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain.; CIBERER-ISCIII, IdiPAZ-CNIO Translational Research Unit in Pediatric Hemato-Oncology, La Paz University Hospital Research Institute; Spanish National Cancer Center, Madrid, Spain.; Advanced Therapies Mixed Unit, CIEMAT/IIS-FJD, Madrid, Spain.; Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, Spain., Ramírez-Orellana M; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain.; Hospital Infantil Universitario Niño Jesús, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain., Torrebadell M; Institut de Recerca Pediàtrica Sant Joan de Déu; Department of Hematology, Hospital Sant Joan de Déu, Barcelona, Spain., Díaz VM; OneChain Immunotherapeutics S.L, Barcelona, Spain.; Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain., Toribio ML; Centro de Biología Molecular Severo Ochoa CSIC-UAM, Madrid, Spain. mtoribio@cbm.csic.es., Sánchez-Martínez D; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain. dsanchez@iisaragon.es.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain. dsanchez@iisaragon.es.; Aragon Health Research Institute (IIS Aragón), Zaragoza, Spain. dsanchez@iisaragon.es.; Aragon Foundation for Research & Development (ARAID), Zaragoza, Spain. dsanchez@iisaragon.es., Menéndez P; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain. pmenendez@carrerasresearch.org.; Red Española de Terapias Avanzadas (TERAV+), Instituto de Salud Carlos III, Madrid, Spain. pmenendez@carrerasresearch.org.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. pmenendez@carrerasresearch.org.; Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain. pmenendez@carrerasresearch.org.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. pmenendez@carrerasresearch.org.; Institut de Recerca Hospital Sant Joan de Déu-Pediatric Cancer Center Barcelona (SJD-PCCB), Barcelona, Spain. pmenendez@carrerasresearch.org.
Source: Journal of hematology & oncology [J Hematol Oncol] 2025 Jul 01; Vol. 18 (1), pp. 69. Date of Electronic Publication: 2025 Jul 01.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1756-8722
DOI:10.1186/s13045-025-01715-0